logo
Feather forensics offers a way to root out poachers

Feather forensics offers a way to root out poachers

This story was originally published by bioGraphic and appears here as part of the Climate Desk collaboration
Every year, the illegal wildlife trade ensnares millions of wild birds in a vast global industry worth up to US $23 billion. Poaching for the black market affects a huge diversity of life, including nearly half of all bird species. Songbirds and parrots are particularly popular targets, with thousands illegally caught and traded every year.
Proving that a bird sold as a pet was born in captivity, rather than poached from the wild, is difficult. Tracking a bird's origins, says Katherine Hill, an invasive species biologist at the University of Adelaide in Australia, relies on paperwork, 'which can obviously be forged relatively simply.'
Over the past few decades, however, scientists have been developing a technique that can hint at whether an animal hails from the wild or captivity. Known as stable isotope analysis, the approach involves analyzing the abundance of different forms of certain chemical elements in an animal's tissues.
Stable isotope analysis works on birds because their feathers lock in identifiable chemical signatures as they grow, creating a snapshot of a period of the bird's life, Hill says. Captive birds, for example, tend to eat corn and sorghum. Wild birds eat more fruits, nuts, and wild plant seeds. This altered diet skews the chemical analysis, giving scientists an accurate way to gauge what kinds of foods a bird has been eating.
Scientists have used stable isotope analysis to study bird diets for s everal years. But earlier projects aiming to tease out birds' origins largely focused on a few endangered parrot species with limited diets, small populations, or small ranges. Hill wanted to see if she could apply the technique to parrot species with relatively large geographic ranges that eat a wider variety of foods. In particular, she focused on four common Australian parrots that are popular as pets—galahs (Eolophus roseicapilla), sulphur-crested cockatoos (Cacatua galerita), little corellas (Cacatua sanguinea), and long-billed corellas (Cacatua tenuirostris).
Beginning in December 2020, Hill set out around Adelaide, where she scanned the streets for the vibrant white, yellow, or pink shocks of wild parrot feathers. COVID-19-related lockdowns meant it was difficult for Hill and her colleagues to visit zoos or aviaries to collect the feathers of captive parrots. Instead, they created a community-science initiative to collect feathers from the public. Spreading the word through social media, local news organizations, and other places likely to catch the eyes of animal lovers, the scientists harnessed dozens of volunteers from across South Australia who collectively sent in thousands of feathers they found in the wild or gathered from the bottom of their pets' cages. The project became a way for people to connect with nature, Hill says.
Pooling the feathers by species, and splitting them by whether they came from wild or captive birds, Hill and her colleagues found that stable isotope analysis can accurately distinguish between wild and captive galahs nearly 90 percent of the time, and the other parrot species 74 percent of the time. The isotope research from those four parrot species will provide data that other scientists can use in future studies as well.
The technique offers a potent way to identify poached birds. But it is possible, says Hill, to cheat the test. If a captive bird is fed a diet similar to what a wild one would eat—or if wild birds have particularly diverse diets or access to something similar to pet food—it could muddy the results. But, says Hill, when used with other tools, isotope analysis could tip off law enforcement that a bird might have been poached, giving the authorities reason to investigate further.
The value of stable isotope analysis is also constrained by time, Hill says. Because birds regularly grow and molt their feathers, each piece of plumage only reflects the time between molts. For many parrots, that's about a year. This means the technique would be best at identifying birds that were captured from the wild within that time frame.
Astrid Andersson, a conservation biologist at the University of Hong Kong, says the effectiveness of stable isotope analysis to distinguish between captive and wild parrots aligns with previous research, including her own work on a Chinese population of yellow-crested cockatoos.
'It's really important to expand the number of species that have this stable isotope data,' says Andersson. Different species need their own stable isotope datasets, she says. 'We need to build up the database that authorities could potentially refer to.'
Wildlife authorities don't often use stable isotope analysis in their investigations and, to date, the technique isn't being regularly used in bird-poaching investigations. But analyzing feathers could be a powerful new tool in the anti-poaching toolbox, says Kate Brandis, a wildlife forensics expert at the University of New South Wales in Australia. 'This is still a developing area,' she says. But research like Hill's is 'demonstrating that this does have a place in fighting the illegal wildlife trade.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alberta health experts say wastewater testing may offer early detection of measles
Alberta health experts say wastewater testing may offer early detection of measles

Global News

time4 days ago

  • Global News

Alberta health experts say wastewater testing may offer early detection of measles

Health experts embraced it as a valuable tool to help track the spread of COVID-19 during the pandemic. Now, those same experts say it may also help health officials get the jump on preventing measles outbreaks in places like Alberta, a province that now has the notorious reputation of having surpassed the entire United States for the number of lab-confirmed cases of the highly-infectious virus. 'I think surveillance is best when you have a number of different ways of following the disease and molecular testing of wastewater proved its worth during COVID,' said Alberta's former chief public health officer, Dr. James Talbot. 'It identifies when a virus has moved into new territory. It can be the earliest signal for that. It tells you whether the situation is getting better or worse, which is very important to know,' added Talbot. Story continues below advertisement 'And finally, when you're taking measures to control it, that kind of surveillance can tell you whether the measures are working or not.' 2:09 Data from wastewater helps ease Alberta's pandemic data problem Dr. Xiaoli Pang, a professor in the Department of Laboratory Medicine and Pathology at the University of Alberta, has been testing wastewater from 12 treatment plants across Alberta, once a week, since April 1. 'We never can replace clinical testing, because we are not able to detect who is infected, how many people are infected — we are just, through the community, (doing) population-based monitoring,' said Pang. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Because the incubation period for measles can be up to three weeks — from exposure to the appearance of symptoms — Pang said the testing may be able to provide health officials with early detection of where outbreaks could occur, providing them with valuable information on where to focus their vaccination and education efforts. Story continues below advertisement The testing can also distinguish between the disease strain of measles and the strain used to produce the vaccine — which means it might also be useful to help determine how much of the population in a particular region has already been vaccinated. 'This disease is a predictable disease. If you apply a vaccine, you get protected, so that is important information for public health,' added Pang. One of the shortcomings of the wastewater testing is it likely does not accurately reflect the infection rate in babies or young children who may still use a diaper. According to the Alberta government, about a third of the people in the province infected with measles are under 5 years of age. But many health experts claim use of the existing system of clinical testing is likely also underestimating the size of the measles problem in Alberta. 'The surveillance system that's in place right now is likely to be undercounting the number of cases,' said Talbot, 'particularly in the summer, because there's so many opportunities during the summer for the measles virus to spread, as kids go to sports camps, Bible camps, family gatherings, summer camps and big events too, like the Calgary Stampede.' View image in full screen A special computerized device, installed over a modified manhole in Calgary, was used to help test for the Covid-19 virus during the pandemic. Global News Despite the promising results, however, Pang said the wastewater testing program is short on funding. Story continues below advertisement 'I'm only able to plan to monitor measles until end of this year,' said Pang. 'I believe this virus is (going to) continue to cause a huge problem and we may not be able to continue. 'So that is a challenge.' 2:05 COVID-19: What is wastewater testing, and how effective is it? Global News asked the Alberta government if it plans to use wastewater testing to help in the fight against measles. The Ministry of Primary and Preventative Health Services provided a written statement that said, 'public health officials are reviewing this data to determine its relevance during the current outbreak. However, because measles is a notifiable disease with clear, recognizable symptoms, the vast majority of cases are identified through routine public health surveillance.' The statement continued, 'At this stage, measles wastewater surveillance is considered an exploratory tool and is not anticipated to support earlier case detection, as public health already has a clear understanding of where cases are occurring and how the virus is spreading.' Story continues below advertisement Talbot, however, who has been highly critical of the province's efforts to prevent the spread of measles, believes wastewater testing could be another valuable tool for the province to use. 'You know, the provincial government is fond of saying that getting immunized is a personal decision, which of course it is,' said Talbot. 'But they never go on to make the second point, which is that although it's a personal decision, it has consequences for other people.'

New study surfaces explosive risk hidden beneath Antarctic ice
New study surfaces explosive risk hidden beneath Antarctic ice

National Observer

time4 days ago

  • National Observer

New study surfaces explosive risk hidden beneath Antarctic ice

This story was originally published by The Guardian and appears here as part of the Climate Desk collaboration The melting of glaciers and ice caps by the climate crisis could unleash a barrage of explosive volcanic eruptions, a study suggests. The loss of ice releases the pressure on underground magma chambers and makes eruptions more likely. This process has been seen in Iceland, an unusual island that sits on a mid-ocean tectonic plate boundary. But the research in Chile is one of the first studies to show a surge in volcanism on a continent in the past, after the last ice age ended. Global heating caused by the burning of fossil fuels is now melting ice caps and glaciers across the world. The biggest risk of a resurgence of volcanic eruptions is in west Antarctica, the researchers said, where at least 100 volcanoes lie under the thick ice. This ice is very likely to be lost in the coming decades and centuries as the world warms. Volcanic eruptions can cool the planet temporarily by shooting sunlight-reflecting particles into the atmosphere. However, sustained eruptions would pump significant greenhouse gases into the atmosphere, including carbon dioxide and methane. This would further heat the planet and potentially create a vicious circle, in which rising temperatures melt ice that leads to further eruptions and more global heating. Pablo Moreno-Yaeger, at the University of Wisconsin-Madison, US, who led the research, said: 'As glaciers retreat due to climate change, our findings suggest these volcanoes go on to erupt more frequently and more explosively.' The research, which was presented at the Goldschmidt geochemistry conference in Prague, and is in the final stages of review with an academic journal, involved camping high in the Andes, among active and dormant volcanoes. As ice caps and glaciers melt, the pressure they put on volcanoes is released — and the magma that has built up beneath them is more likely to erupt, leading to a vicious circle of heating. Detailed work on one volcano, called Mocho-Choshuenco, used radioisotope dating to estimate the age of volcanic rocks produced before, during and after the last ice age, when the 1,500-metre-thick Patagonian ice sheet covered the area. Analysis of the minerals in the rocks also revealed the depth and temperature at which the rocks formed. This data revealed that thick ice cover had suppressed the volume of eruptions between 26,000 and 18,000 years ago, allowing a large reservoir of magma to build up 10-15km (6.2-9.3 miles) below the surface. After the ice melted, from about 13,000 years ago, the pressure on the magma chamber was released, gasses in the liquid or molten rock expanded and explosive eruptions followed. 'We found that following deglaciation, the volcano starts to erupt way more, and also changes composition,' said Moreno-Yaeger. The composition changed as the magma melted crustal rocks while eruptions were suppressed. This made the molten rock more viscous and more explosive on eruption. 'Our study suggests this phenomenon isn't limited to Iceland, where increased volcanicity has been observed, but could also occur in Antarctica,' he said. 'Other continental regions, like parts of North America, New Zealand and Russia, also now warrant closer scientific attention.' Previous research has shown volcanic activity increased globally by two to six times after the last ice age, but the Chilean study was one of the first to show how this happened. A similar phenomenon was reported via the analysis of rocks in eastern California in 2004. A recent review by scientists found there had been relatively little study on how the climate crisis had been affecting volcanic activity. They said more research was 'critically important' in order to be better prepared for the damage caused by volcanic eruptions to people and their livelihoods and for possible climate-volcano feedback loops that could amplify the climate crisis. For example, more extreme rainfall is also expected to increase violent explosive eruptions.

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Cision Canada

time5 days ago

  • Cision Canada

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by renewed regulatory scrutiny of mRNA vaccines at both federal and state levels, casting a shadow over ongoing cancer research efforts. Meanwhile, the incidence of cancers—especially gastrointestinal and colorectal cancers among younger populations—is on the rise, heightening the need for new therapeutic approaches. In response, a new generation of biotech companies is stepping forward with promising clinical milestones on the horizon, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zai Lab Limited (NASDAQ: ZLAB), GeoVax Labs, Inc. (NASDAQ: GOVX), OS Therapies (NYSE-American: OSTX), and SELLAS Life Sciences Group, Inc. (NASDAQ: SLS). Industry forecasts suggest the global oncology drug market could climb past US$900 billion by 2034. Within that, next-generation cancer treatments —powered by advances in personalized and precision medicine—are expected to reach US$175.2 billion, according to Precedence Research, growing at a compound annual rate of 7.35%. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) just rolled out an expanded translational data review package that tightens the scientific case for pelareorep, its intravenously delivered oncolytic virus. Fresh analyses from the GOBLET gastrointestinal‑cancer study and the AWARE‑1 breast‑cancer study shows pelareorep actively replicating inside tumors, switching on interferon signaling in the immune system, and drawing tumor‑infiltrating lymphocytes into the cancer microenvironment. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Investigators also recorded a clear increase in PD‑L1 expression, a checkpoint marker that helps immune cells recognize tumors, and tracked newly expanded T‑cell clones in the blood that matched those inside shrinking lesions. Together, these findings suggest pelareorep can convert "cold" tumors into "hot" ones that respond better to modern immunotherapies. "The collection of data here show that pelareorep works how a cancer immunotherapy should work," said Jared Kelly, CEO of Oncolytics. "Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs." Two GOBLET cohorts—metastatic pancreatic ductal adenocarcinoma (mPDAC) and anal cancer—remain open. Management plans to outline the next clinical milestones before the end of the third quarter. Clinical outcomes already hint at real‑world benefit. In more than 100 first‑line mPDAC patients, pelareorep‑based regimens achieved a two‑year overall‑survival rate of 21.9%, compared with the historical benchmark of 9.2%. A separate single‑arm study that paired pelareorep with chemotherapy and a checkpoint blocker produced a 62% objective response rate. No immune checkpoint therapy is approved in this cancer today, which makes the signal especially noteworthy. Progress extends to hormone‑receptor‑positive, HER2‑negative metastatic breast cancer (HR+/HER2‑ mBC). Across two randomized trials, pelareorep added more than ten months of median overall survival. In BRACELET‑1, the drug nearly doubled median progression‑free survival to 12.1 months versus 6.4 months in the control arm, suggesting durable disease control. Next week, Oncolytics will host a KOL webinar on July 22 featuring leading GI and immuno-oncology experts to discuss pelareorep's data and positioning in pancreatic and gastrointestinal cancers. Participating physicians include the GOBLET trial's primary investigator as well as global leaders in immunotherapy and clinical trial design, underscoring the growing interest in pelareorep's mechanism and outcomes. To steer these data toward value‑creating deals and late‑stage trials, Oncolytics Biotech strengthened its leadership earlier this year. The board tapped industry veteran Jared Kelly for the CEO seat and named Andrew Aromando Chief Business Officer. Both executives helped guide Ambrx Biopharma into a $2‑billion sale to Johnson & Johnson, giving them a playbook for capital‑efficient development and strategic partnering. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications," said Kelly. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy." As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution," said Aromando. "With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Pelareorep currently holds FDA Fast Track designation in both mPDAC (pancreatic cancer) and HR+/HER2- mBC (breast cancer), with Orphan Drug status for pancreatic cancer in the U.S. and Europe. In other recent industry developments and happenings in the market include: Zai Lab Limited (NASDAQ: ZLAB) recently reported that its Phase 3 FORTITUDE‑101 study found bemarituzumab plus mFOLFOX6 significantly improved overall survival over chemotherapy alone in first‑line fibroblast growth factor receptor 2b (FGFR2b)‑positive gastric and gastroesophageal junction cancers. The antibody becomes the first FGFR2b inhibitor to post a statistically and clinically meaningful survival benefit, and the company plans a rapid regulatory filing in China under its Breakthrough Therapy designation. "Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of FGFR2b-positive gastric cancer," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The success of the global Phase 3 FORTITUDE-101 study highlights the potential of bemarituzumab to redefine the standard of care for a patient population that has faced poor outcomes with existing therapies. We are proud to have contributed meaningfully to this pivotal trial, including a substantial number of patients enrolled in China. Based on these results, and the regulatory Breakthrough Designation, we plan to move rapidly toward regulatory submission in China to bring this transformative therapy to patients as quickly as possible." GeoVax Labs, Inc. (NASDAQ: GOVX) recently stated that the FDA's curative‑intent approval of Keytruda for head and neck cancer strengthens the rationale for its planned Phase 2 trial combining Gedeptin and pembrolizumab. "We believe Gedeptin's tumor-targeted cytotoxicity can enhance immunotherapy efficacy, particularly in the perioperative window where anti-tumor immunity can be primed," added Dr. Kelly McKee, GeoVax's Chief Medical Officer. "We are excited to embark on the next phase of Gedeptin development as we attempt to build on the important advances being made in this disease." The study, expected to launch in 2026, will give Gedeptin intratumorally before surgery to trigger local cytotoxicity, then add checkpoint inhibition to boost systemic immunity. Endpoints include pathologic response, recurrence rates, and immune biomarkers, aligning with guidance in a recent New England Journal of Medicine editorial. OS Therapies (NYSE-American: OSTX) has locked in an End‑of‑Phase 2 FDA meeting for 27 August 2025 to discuss a rolling Biologics License Application for OST‑HER2 in recurrent, lung‑metastatic osteosarcoma, while parallel regulatory consultations are set with the EMA and the UK MHRA. "We are making significant progress towards our primary objective of obtaining regulatory approval for OST-HER2 in recurrent, pulmonary metastatic osteosarcoma prior to the sunsetting of the rare pediatric disease priority review voucher ("PRV") program," said Paul Romness, MPH, Chairman & CEO of OS Therapies. "We strongly believe in the promise of the listeria immunotherapy platform to help prevent and treat cancer, and intend to judiciously deploy our capital to focus on the OST-HER2 approval while advancing our other clinical programs without deploying significant capital or running other clinical studies while we wait for the OST-HER2 approval and related PRV sale." The company is also advancing a Phase 1 prostate‑cancer immunotherapy, OST‑504, with full data expected later in 2025. OST‑HER2 already carries Rare Pediatric Disease, Fast Track, and Orphan Drug designations, positioning the program for a potential Priority Review Voucher and accelerated approvals in multiple markets. SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) met every primary endpoint in its Phase 2 trial of SLS009 in relapsed/refractory acute myeloid leukemia-myelodysplasia-related changes (AML MR), delivering a 44% overall response rate at the optimal 30 mg twice‑weekly dose and a median overall survival of 8.9 months—far above the 2.4 month historical benchmark. The CDK9 inhibitor also showed a 50% response rate in high‑risk ASXL1‑mutated and M4/M5 subgroups, with no dose‑limiting toxicities reported. "We are excited to report that our Phase 2 trial met all key endpoints, with clinical responses and survival outcomes that exceed targeted expectations and historical benchmarks," said Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS. "AML remains an area of urgent unmet medical need, particularly for patients with relapsed or refractory disease, where standard treatments are often ineffective and poorly tolerated. What sets SLS009 apart is its consistent efficacy across a broad range of molecular subtypes." Following FDA guidance, the company will launch an 80‑patient randomized study in newly diagnosed first‑line AML by Q1 2026 to support a potential New Drug Application. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store